Trial Profile
26-Week Open-Label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Most Recent Episode Manic)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2022
Price :
$35
*
At a glance
- Drugs Ziprasidone (Primary)
- Indications Bipolar I disorders
- Focus Adverse reactions; Registrational
- Sponsors Pfizer
- 01 Oct 2022 Results assessing longer-term effectiveness, safety, and tolerability of open-label ziprasidone in children and adolescents with bipolar I disorder , published in the Journal of Child and Adolescent Psychopharmacology.
- 03 Sep 2020 Status changed from recruiting to discontinued. Reason the study was stopped: Pfizer has decided to perform the pre-specified final analysis at the current enrollment using a re-estimation of the sample size.
- 03 Aug 2020 Planned End Date changed from 7 Jul 2021 to 6 Aug 2020.